Nature Reviews Drug Discovery

Nature Reviews Drug Discovery is a monthly review journal published by Nature Portfolio that was launched in 2002, covering the science and business of drug discovery and development, with a 2025 Journal Impact Factor of 91.2《自然综述：药物发现》（Nature Reviews Drug Discovery）是 Nature Portfolio 出版的月刊综述期刊，2002 年创刊，覆盖药物发现与开发的科学与商业面向，2025 年期刊影响因子为 91.2。

Scope

• It is aimed at everyone working in the drug discovery and development arena, spanning target discovery and validation, preclinical research, clinical trials and drug regulation该刊面向药物发现与开发各环节的从业者，涵盖靶点发现与验证、临床前研究、临床试验与药品监管。
• Other subjects include high-throughput screening, novel therapeutic approaches, rational drug design, medicinal chemistry and natural products其他主题包括高通量筛选、新型治疗策略、理性药物设计、药物化学与天然产物。
• It also covers bioinformatics and chemoinformatics, pharmacology, toxicology, biomarkers and omics technologies亦涵盖生物信息学与化学信息学、药理学、毒理学、生物标志物与组学技术。
• Further topics are drug delivery, biopharmaceuticals, biotechnology and vaccines进一步包括药物递送、生物制药、生物技术与疫苗。^[1]
• The journal additionally addresses business development, licensing, market analysis, strategic issues, industry trends, patent law and pharmacoeconomics此外还涉及业务拓展、许可、市场分析、战略议题、行业趋势、专利法与药物经济学。
• Each issue includes news stories that investigate the hottest topics, timely summaries of key primary research papers and updates on new drug approvals每期包含追踪热点议题的新闻、关键原始研究论文的及时摘要，以及新药审批进展更新。
• Article types include Reviews, Perspectives, news stories and Research Highlights文章类型包括综述、观点、新闻与研究亮点。

History

• Nature Reviews Drug Discovery was launched in 2002 and has been published monthly by Nature Portfolio, part of Springer Nature, throughout its history该刊于 2002 年创刊，始终由施普林格·自然旗下的 Nature Portfolio 每月出版。
• Its founding Chief Editor was Adam Smith, who joined Nature Publishing Group in 2001 to establish the new title, which launched in 2002创刊主编为 Adam Smith，他于 2001 年加入 Nature 出版集团以创办该刊，期刊于 2002 年面世。
• Peter Kirkpatrick joined the launch team as an Associate Editor in 2001 and has been Chief Editor since 2004Peter Kirkpatrick 于 2001 年作为副编辑加入创刊团队，自 2004 年起任主编。
• It appears monthly, and the correct abbreviation for abstracting and indexing is Nat. Rev. Drug Discov., with ISSN 1474-1776 and eISSN 1474-1784该刊每月出版，用于文摘与索引的规范缩写为 Nat. Rev. Drug Discov.，印刷版与在线版分别以 ISSN 1474-1776 与 eISSN 1474-1784 标识。
• It has remained a subscription-based hybrid journal rather than a fully open-access title该刊始终为订阅制混合期刊，并非完全开放获取。
• Its Journal Impact Factor was 122.7 in 2023, 101.8 in 2024 and 91.2 in 2025其期刊影响因子 2023 年为 122.7，2024 年为 101.8，2025 年为 91.2。
• It has published widely cited reviews such as one on natural products in drug discovery该刊发表过诸如关于天然产物在药物发现中的作用的被广泛引用的综述。^[2]

Editors

• Like other Nature titles, the journal has no external editorial board, and all editorial decisions are made by a team of full-time professional editors与其他 Nature 系列期刊一样，该刊不设外部编委会，所有编辑决定均由全职专业编辑团队作出。
• The Chief Editor is Peter Kirkpatrick, a chemist by training who studied vancomycin-group antibiotics at the University of Cambridge and has led the journal since 2004现任主编为 Peter Kirkpatrick，他受过化学训练，曾在剑桥大学研究万古霉素类抗生素，自 2004 年起领导该刊。
• The Senior Editors are Sarah Crunkhorn, based in the United States, and Alex Eccleston and M. Teresa Villanueva, both based in London in the United Kingdom高级编辑包括常驻美国的 Sarah Crunkhorn，以及常驻英国伦敦的 Alex Eccleston 与 M. Teresa Villanueva。
• A Senior Editor for news, Katie Kingwell, handles the journal's news and feature content and has held the role since 2014新闻高级编辑 Katie Kingwell 负责该刊的新闻与专题内容，自 2014 年起担任该职。
• Reviews and Perspectives are commissioned, with editors selecting and inviting experts and developing the scope with them before peer review综述与观点文章以约稿为主，由编辑遴选并邀请专家，并在同行评审前与作者共同确定范围。
• Each manuscript is peer reviewed by typically two to three external experts and passes through scientific editing, artwork development and copy editing before publication每篇稿件通常由两到三位外部专家评审，发表前经历科学编辑、图件制作与文字编辑。
• Under Nature Portfolio policy, peer review is single-anonymised by default, with a double-anonymised option available依照 Nature Portfolio 政策，同行评审默认单盲，另设双盲选项。